Analysis of Soluble Interleukin-2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD.

IF 3.9 2区医学 Q1 CLINICAL NEUROLOGY

Annals of Clinical and Translational Neurology Pub Date : 2025-09-05 DOI:10.1002/acn3.70186

Philipp Klyscz, Carolin Otto, Klemens Ruprecht, Susanna Asseyer, Hannes Ole Tiedt, Christian Meisel, Judith Bellmann-Strobl, Friedemann Paul, Patrick Schindler

{"title":"Analysis of Soluble Interleukin-2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD.","authors":"Philipp Klyscz, Carolin Otto, Klemens Ruprecht, Susanna Asseyer, Hannes Ole Tiedt, Christian Meisel, Judith Bellmann-Strobl, Friedemann Paul, Patrick Schindler","doi":"10.1002/acn3.70186","DOIUrl":null,"url":null,"abstract":"Objective: Soluble interleukin-2 receptor (sIL-2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) pathogenesis. However, sIL-2R has so far not been evaluated in these conditions. Here, we compared sIL-2R levels in serum and cerebrospinal fluid (CSF) of patients with aquaporin-4-IgG-seropositive and seronegative (AQP4-IgG+/-) NMOSD, MOGAD, and noninflammatory neurologic disorders (NINDs), and assessed the prognostic value of sIL-2R for future attacks.Methods: Retrospective analysis of real-world data of patients treated at Charité-Universitätsmedizin Berlin was conducted (45 MOGAD, 14 AQP4-IgG+NMOSD, 10 AQP4-IgG-NMOSD, 69 NINDs) between 2010 and 2024. Mean (SD) follow-up time was 40 (35) months. sIL-2R differences were assessed by linear mixed models. Cox regression analysis was performed to investigate the predictive value for subsequent attacks.Results: Serum sIL-2R was higher in AQP4-IgG+NMOSD (estimated marginal mean [EMM] 802 IU/mL) and MOGAD (569 IU/mL) compared to NINDs (404 IU/mL). In patients with a first manifestation of MOGAD, but not NMOSD, serum sIL-2R (HR = 9.07 [95% CI 1.37-60.01]) and CSF sIL-2R (HR = 3.27 [95% CI 0.61-17.45]) levels were predictive for subsequent attacks.Interpretation: Serum sIL-2R is elevated in AQP4-IgG+NMOSD and MOGAD and may be a prognostic biomarker for a relapsing disease course in MOGAD.","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/acn3.70186","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Soluble interleukin-2 receptor (sIL-2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) pathogenesis. However, sIL-2R has so far not been evaluated in these conditions. Here, we compared sIL-2R levels in serum and cerebrospinal fluid (CSF) of patients with aquaporin-4-IgG-seropositive and seronegative (AQP4-IgG+/-) NMOSD, MOGAD, and noninflammatory neurologic disorders (NINDs), and assessed the prognostic value of sIL-2R for future attacks.

Methods: Retrospective analysis of real-world data of patients treated at Charité-Universitätsmedizin Berlin was conducted (45 MOGAD, 14 AQP4-IgG+NMOSD, 10 AQP4-IgG-NMOSD, 69 NINDs) between 2010 and 2024. Mean (SD) follow-up time was 40 (35) months. sIL-2R differences were assessed by linear mixed models. Cox regression analysis was performed to investigate the predictive value for subsequent attacks.

Results: Serum sIL-2R was higher in AQP4-IgG+NMOSD (estimated marginal mean [EMM] 802 IU/mL) and MOGAD (569 IU/mL) compared to NINDs (404 IU/mL). In patients with a first manifestation of MOGAD, but not NMOSD, serum sIL-2R (HR = 9.07 [95% CI 1.37-60.01]) and CSF sIL-2R (HR = 3.27 [95% CI 0.61-17.45]) levels were predictive for subsequent attacks.

Interpretation: Serum sIL-2R is elevated in AQP4-IgG+NMOSD and MOGAD and may be a prognostic biomarker for a relapsing disease course in MOGAD.

查看原文本刊更多论文

可溶性白介素-2受体作为NMOSD和MOGAD预后生物标志物的分析。

目的：可溶性白细胞介素-2受体（sIL-2R）是T细胞活性的生物标志物。T细胞参与视神经脊髓炎谱系障碍（NMOSD）和髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）的发病机制。然而，sIL-2R迄今尚未在这些条件下进行评估。在这里，我们比较了水通道蛋白-4- igg血清阳性和血清阴性（AQP4-IgG+/-） NMOSD、MOGAD和非炎症性神经疾病（NINDs）患者血清和脑脊液（CSF）中的sIL-2R水平，并评估了sIL-2R对未来发作的预后价值。方法：回顾性分析2010年至2024年间在Charité-Universitätsmedizin Berlin接受治疗的患者的真实数据（MOGAD 45例，AQP4-IgG+NMOSD 14例，AQP4-IgG-NMOSD 10例，NINDs 69例）。平均（SD）随访时间40（35）个月。采用线性混合模型评估sIL-2R差异。采用Cox回归分析研究对后续攻击的预测价值。结果：AQP4-IgG+NMOSD（估计边际平均值[EMM] 802 IU/mL）和MOGAD （569 IU/mL）血清sIL-2R高于NINDs （404 IU/mL）。在首次表现为MOGAD而非NMOSD的患者中，血清sIL-2R （HR = 9.07 [95% CI 1.37-60.01]）和CSF sIL-2R （HR = 3.27 [95% CI 0.61-17.45]）水平可预测随后的发作。解释：血清sIL-2R在AQP4-IgG+NMOSD和MOGAD中升高，可能是MOGAD复发病程的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Clinical and Translational Neurology Medicine-Neurology (clinical)

CiteScore

9.10

自引率

1.90%

发文量

218

审稿时长

8 weeks

期刊介绍： Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.